Patents by Inventor Aileen L. Pangan

Aileen L. Pangan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240122923
    Abstract: The present disclosure is directed to methods for treating hidradenitis suppurativa (HS) using the selective JAK1 inhibitor upadacitinib.
    Type: Application
    Filed: September 28, 2023
    Publication date: April 18, 2024
    Inventors: Aileen L. PANGAN, Mohamed-Eslam F. Mohamed
  • Publication number: 20230399333
    Abstract: The present disclosure relates to processes for preparing (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, solid state forms thereof, and corresponding pharmaceutical compositions, methods of treatment (including treatment of rheumatoid arthritis and various spondyloarthritic conditions, including types of axial spondyloarthritis (axSpA)), kits, methods of synthesis, and products-by-process. In various aspects, provided are methods for treating active non-radiographic axSpA (nr-axSpA) and methods for treating active ankylosing spondylitis (AS).
    Type: Application
    Filed: August 21, 2023
    Publication date: December 14, 2023
    Inventors: Mohamed-Eslam F. Mohamed, Ahmed A. Othman, Aileen L. Pangan, In-Ho Song, Ben Klünder, Jeffrey W. Voss, Robert J. Padley, Heidi S. Camp
  • Publication number: 20230364080
    Abstract: Provided are methods for treating various spondyloarthritic and psoriatic conditions, including types of axial spondyloarthritis (axSpA), psoriatic arthritis (PsA), and psoriasis (PsO), with the JAK1 inhibitor, upadacitinib free base or pharmaceutically acceptable salt thereof. In various aspects, provided are methods for treating active non-radiographic axSpA (nr-axSpA), methods for treating active ankylosing spondylitis (AS), methods for treating active psoriatic arthritis (PsA), and methods for treating active psoriasis (PsO).
    Type: Application
    Filed: October 12, 2022
    Publication date: November 16, 2023
    Inventors: Aileen L. Pangan, Jaclyn Kay Anderson, In-Ho Song, Jose Jeffrey V. Enejosa
  • Patent number: 11795175
    Abstract: The present disclosure relates to processes for preparing (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine carboxamide, solid state forms thereof, and corresponding pharmaceutical compositions, methods of treatment (including treatment of rheumatoid arthritis), kits, methods of synthesis, and products-by-process.
    Type: Grant
    Filed: March 1, 2023
    Date of Patent: October 24, 2023
    Assignee: AbbVie Inc.
    Inventors: Mohamed-Eslam F. Mohamed, Ahmed A. Othman, Ben Klünder, Aileen L. Pangan, Jeffrey W. Voss, Robert J. Padley, Heidi S. Camp
  • Patent number: 11780848
    Abstract: The present disclosure relates to processes for preparing (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, solid state forms thereof, and corresponding pharmaceutical compositions, methods of treatment (including treatment of rheumatoid arthritis and various spondyloarthritic conditions, including types of axial spondyloarthritis (axSpA)), kits, methods of synthesis, and products-by-process. In various aspects, provided are methods for treating active non-radiographic axSpA (nr-axSpA) and methods for treating active ankylosing spondylitis (AS).
    Type: Grant
    Filed: March 1, 2023
    Date of Patent: October 10, 2023
    Assignee: AbbVie Inc.
    Inventors: Mohamed-Eslam F. Mohamed, Ahmed A. Othman, Aileen L. Pangan, In-Ho Song, Ben Klünder, Jeffrey W. Voss, Robert J. Padley, Heidi S. Camp
  • Publication number: 20230312594
    Abstract: The present disclosure relates to processes for preparing (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-?]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, solid state forms thereof, and corresponding pharmaceutical compositions, methods of treatment (including treatment of rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthrritis), kits, methods of synthesis, and products-by -process.
    Type: Application
    Filed: March 1, 2023
    Publication date: October 5, 2023
    Inventors: Ayman Allian, Jayanthy Jayanth, Mohamed-Eslam F. Mohamed, Mathew Mulhem, Fredrik Lars Nordstrom, Ahmed A. Othman, Michael J. Rozema, Lakshmi Bhagavatula, Patrick J. Marroum, Peter T. Mayer, Ahmad Y. Sheikh, Thomas B. Borchardt, Ben Klünder, Aileen L. Pangan, Jaclyn Kay Anderson, In-Ho Song, Jose Jeffrey V. Enejosa
  • Patent number: 11773106
    Abstract: The present disclosure relates to processes for preparing (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, solid state forms thereof, and corresponding pharmaceutical compositions, methods of treatment (including treatment of rheumatoid arthritis and various spondyloarthritic conditions, including types of axial spondyloarthritis (axSpA)), kits, methods of synthesis, and products-by-process. In various aspects, provided are methods for treating active non-radiographic axSpA (nr-axSpA) and methods for treating active ankylosing spondylitis (AS).
    Type: Grant
    Filed: March 1, 2023
    Date of Patent: October 3, 2023
    Assignee: AbbVie Inc.
    Inventors: Mohamed-Eslam F. Mohamed, Ahmed A. Othman, Aileen L. Pangan, In-Ho Song, Ben Klünder, Jeffrey W. Voss, Robert J. Padley, Heidi S. Camp
  • Patent number: 11767326
    Abstract: The present disclosure relates to processes for preparing (3S,4R)-3-ethyl-4-(3Himidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, solid state forms thereof, and corresponding pharmaceutical compositions, methods of treatment (including treatment of rheumatoid arthritis and atopic dermatitis), kits, methods of synthesis, and products-by-process.
    Type: Grant
    Filed: March 1, 2023
    Date of Patent: September 26, 2023
    Assignee: AbbVie Inc.
    Inventors: Aileen L. Pangan, Henrique D. Teixeira, Mohamed-Eslam F. Mohamed, Ahmed A. Othman, Ben Klünder, Jeffrey W. Voss, Robert J. Padley, Heidi S. Camp
  • Publication number: 20230271974
    Abstract: The present disclosure relates to processes for preparing (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, solid state forms thereof, and corresponding pharmaceutical compositions, methods of treatment(including treatment of rheumatoid arthritis and atopic dermatitis), kits, methods of synthesis, and products-by-process.
    Type: Application
    Filed: March 1, 2023
    Publication date: August 31, 2023
    Inventors: Aileen L. Pangan, Henrique D. Teixeira, Ayman D. Allian, Thomas B. Borchardt, Jayanthy Jayanth, Patrick J. Marroum, Fredrik Lars Nordstrom, Ahmad Y. Sheikh, Mohamed-Eslam F. Mohamed, Ahmed A. Othman, Peter T. Mayer, Ben Klünder
  • Publication number: 20230203050
    Abstract: The present disclosure relates to processes for preparing (3S,4R)-3-ethyl-4-(3Himidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, solid state forms thereof, and corresponding pharmaceutical compositions, methods of treatment(including treatment of rheumatoid arthritis and atopic dermatitis), kits, methods of synthesis, and products-by-process.
    Type: Application
    Filed: March 1, 2023
    Publication date: June 29, 2023
    Inventors: Aileen L. Pangan, Henrique D. Teixeira, Ayman D. Allian, Thomas B. Borchardt, Jayanthy Jayanth, Patrick J. Marroum, Fredrik Lars Nordstrom, Ahmad Y. Sheikh, Mohamed-Eslam F. Mohamed, Ahmed A. Othman, Peter T. Mayer, Ben Klünder
  • Patent number: 11607411
    Abstract: The present disclosure is directed to methods for treating Crohn's disease, and in particular, to methods for inducing clinical remission and/or endoscopic improvement of Crohn's disease, using a JAK1 inhibitor. In certain embodiments, the patient is administered an induction dose of the JAK1 inhibitor to induce clinical remission and/or endoscopic improvement of the Crohn's disease, followed by administration of at least one maintenance dose of the JAK1 inhibitor thereafter. In other embodiments, the present disclosure is directed to methods for treating ulcerative colitis using a JAK1 inhibitor.
    Type: Grant
    Filed: April 1, 2022
    Date of Patent: March 21, 2023
    Assignee: AbbVie Inc.
    Inventors: Ana Paula Machado De Lacerda, Jose Jeffrey V. Enejosa, Aileen L. Pangan, Mohamed-Eslam F. Mohamed, Ahmed A. Othman, Ben Klünder, Wen Zhou
  • Patent number: 11564922
    Abstract: The present disclosure is directed to methods for treating Crohn's disease, and in particular, to methods for inducing clinical remission and/or endoscopic improvement of Crohn's disease, using a JAK1 inhibitor. In certain embodiments, the patient is administered an induction dose of the JAK1 inhibitor to induce clinical remission and/or endoscopic improvement of the Crohn's disease, followed by administration of at least one maintenance dose of the JAK1 inhibitor thereafter. In other embodiments, the present disclosure is directed to methods for treating ulcerative colitis using a JAK1 inhibitor.
    Type: Grant
    Filed: April 28, 2022
    Date of Patent: January 31, 2023
    Assignee: AbbVie Inc.
    Inventors: Aileen L. Pangan, Roopal B. Thakkar, Steven Jungerwirth, Ana Paula Machado De Lacerda, Anne M. Robinson, Mohamed-Eslam F. Mohamed, Ahmed A. Othman, Ben Klünder, Wen Zhou
  • Patent number: 11535624
    Abstract: The present disclosure relates to processes for preparing (3S,4R)-3-ethyl-4-(3Himidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, solid state forms thereof, and corresponding pharmaceutical compositions, methods of treatment (including treatment of rheumatoid arthritis), kits, methods of synthesis, and products-by-process.
    Type: Grant
    Filed: May 27, 2022
    Date of Patent: December 27, 2022
    Assignee: AbbVie Inc.
    Inventors: Ahmed A. Othman, Mohamed-Eslam F. Mohamed, Ben Klünder, Aileen L. Pangan
  • Patent number: 11535625
    Abstract: The present disclosure relates to processes for preparing (3S,4R)-3-ethyl-4-(3Himidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, solid state forms thereof, and corresponding pharmaceutical compositions, methods of treatment (including treatment of rheumatoid arthritis and atopic dermatitis), kits, methods of synthesis, and products-by-process.
    Type: Grant
    Filed: May 27, 2022
    Date of Patent: December 27, 2022
    Assignee: AbbVie Inc.
    Inventors: Aileen L. Pangan, Henrique D. Teixeira, Mohamed-Eslam F. Mohamed, Ahmed A. Othman, Ben Klünder
  • Patent number: 11535626
    Abstract: The present disclosure relates to processes for preparing (3S,4R)-3-ethyl-4-(3Himidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, solid state forms thereof, and corresponding pharmaceutical compositions, methods of treatment (including treatment of rheumatoid arthritis and atopic dermatitis), kits, methods of synthesis, and products-by-process.
    Type: Grant
    Filed: May 27, 2022
    Date of Patent: December 27, 2022
    Assignee: AbbVie Inc.
    Inventors: Aileen L. Pangan, Henrique D. Teixeira, Mohamed-Eslam F. Mohamed, Ahmed A. Othman, Ben Klünder
  • Patent number: 11524964
    Abstract: The present disclosure relates to processes for preparing (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, solid state forms thereof, and corresponding pharmaceutical compositions, methods of treatment (including treatment of rheumatoid arthritis and various spondyloarthritic conditions, including types of axial spondyloarthritis (axSpA)), kits, methods of synthesis, and products-by-process. In various aspects, provided are methods for treating active non-radiographic axSpA (nr-axSpA) and methods for treating active ankylosing spondylitis (AS).
    Type: Grant
    Filed: April 11, 2022
    Date of Patent: December 13, 2022
    Assignee: Abbvie Inc.
    Inventors: Mohamed-Eslam F. Mohamed, Ahmed A. Othman, Ben Klünder, Aileen L. Pangan, In-Ho Song
  • Publication number: 20220306643
    Abstract: The present disclosure relates to processes for preparing (3S,4R)-3-ethyl-4-(3Himidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, solid state forms thereof, and corresponding pharmaceutical compositions, methods of treatment (including treatment of rheumatoid arthritis and atopic dermatitis), kits, methods of synthesis, and products-by-process.
    Type: Application
    Filed: May 27, 2022
    Publication date: September 29, 2022
    Inventors: Aileen L. Pangan, Henrique D. Teixeira, Mohamed-Eslam F. Mohamed, Ahmed A. Othman, Ben Klünder
  • Publication number: 20220298165
    Abstract: The present disclosure relates to processes for preparing (3S,4R)-3-ethyl-4-(3Himidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, solid state forms thereof, and corresponding pharmaceutical compositions, methods of treatment (including treatment of rheumatoid arthritis), kits, methods of synthesis, and products-by-process.
    Type: Application
    Filed: May 27, 2022
    Publication date: September 22, 2022
    Inventors: Ahmed A. Othman, Mohamed-Eslam F. Mohamed, Ben Klünder, Aileen L. Pangan
  • Publication number: 20220298166
    Abstract: The present disclosure relates to processes for preparing (3S,4R)-3-ethyl-4-(3Himidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, solid state forms thereof, and corresponding pharmaceutical compositions, methods of treatment (including treatment of rheumatoid arthritis and atopic dermatitis), kits, methods of synthesis, and products-by-process.
    Type: Application
    Filed: May 27, 2022
    Publication date: September 22, 2022
    Inventors: Aileen L. Pangan, Henrique D. Teixeira, Mohamed-Eslam F. Mohamed, Ahmed A. Othman, Ben Klünder
  • Publication number: 20220281882
    Abstract: The present disclosure relates to processes for preparing (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-?]pyrrolo[2.3-]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, solid state forms thereof, and corresponding pharmaceutical compositions, methods of treatment (including treatment of rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis), kits, methods of synthesis, and products-by-process.
    Type: Application
    Filed: February 9, 2022
    Publication date: September 8, 2022
    Inventors: Ayman Allian, Jayanthy Jayanth, Mohamed-Eslam F. Mohamed, Mathew Mulhern, Fredrik Lars Nordstrom, Ahmed A. Othman, Michael J. Rozema, Lakshmi Bhagavatula, Patrick J. Marroum, Peter T. Mayer, Ahmad Y. Sheikh, Thomas B. Borchardt, Ben Klünder, Aileen L. Pangan, Jaclyn Kay Anderson, In-Ho Song, Jose Jeffrey V. Enejosa